National Institute for Health and Care Excellence The National Institute for Health and Care Excellence approves the Trastuzumab deruxtecan drug for women in England with metastatic or incurable HER2-breast cancer that cannot be removed surgically, making it the first licensed targeted treatment for patients, two years after it was rejected due to its cost effectiveness. Sources: Sky News The Independent